Biogen Inc. (BIIB) — Business segments and KPIs
Revenue by business segment and geography for Biogen Inc., with year-over-year trends.
FY 2025
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| MS Product Revenues | 4.04B | 42.0% |
| TYSABRI product | 1.67B | 17.3% |
| SPINRAZA | 1.55B | 16.1% |
| Fumarate | 1.43B | 14.8% |
| Interferon | 945.6M | 9.8% |
| Revenue by region | ||
| Non-US | 3.57B | 60.1% |
| UNITED STATES | 2.37B | 39.9% |